|Description||AZD2461 is a novel and potent PARP inhibitor with lower affinity to P-glycoprotein. AZD2641 is currently in Phase I clinical study. The study is being conducted to see how it may work to treat solid tumors. The study will also assess the blood levels and action of AZD2461 in the body over a period of time and will indicate whether the drug has a therapeutic effect on solid tumors.|
|Appearance||white solid powder|
|Synonyms||AZD2461; AZD 2461.|
E7449 is an orally bioavailable, potent, small molecule inhibitor of PARP1 and PARP2, which enhances the efficacy of radiotherapy and chemotherapy and has poten...
Olaparib, also known as AZD-2281 or KU-59436, is a small-molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensiti...
1,5-Isoquinolinediol is a PARP1 inhibitor (IC50 value 0.39 - 1.00 μM) and neuroprotective agent leading to an increase up to 8-fold in the absolute frequency of...
Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM, respectively. In HCT-116 and HT-29 cell lines, the ability of ABT-888...
INO1001 is an isoindolinone derivative and potent inhibitor of the nuclear enzyme poly (ADP-ribose) polymerase (PARP) with chemosensitization and radiosensitiza...
Protease-Activated Receptor-2, amide, also known as SLIGKV-NH2, is a highly potent protease-activated receptor-2 (PAR2) activating peptide and can also be utliz...
NMS-P118 is a highly selective Poly(ADP-ribose) Polymerase 1 (PARP-1) inhibitor with excellent ADME, pharmacokinetic profiles and high efficacy in vivo originat...
NVP-TNKS656, also known as TNKS656, is a potent and orally active Tankyrase Inhibitor. With an enthalpy-driven thermodynamic signature of binding, highly favor...
XMD16-5is a novel non-receptor tyrosine kinase TNK2 inhibitor (IC50= 16 nM and 77 nM for D163E and R806Q mutant TNK2, respectively)
Talazoparib, also known as BMN-673, is an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic a...
AZ0108 is an orally bioavailable, PARP1,2,6 inhibitor that causes a multi-polar spindle phenotype at double digit nM concentrations. AZ0108 has been utilized as...
UPF 1069 is a selective PARP2 inhibitor with IC50 of 0.3 μM. It is ~27-fold selective against PARP1.PARP activity is evaluated by utilizing commercially availab...
TFLLR-NH2, derived from the protease-activated receptor-1 (PAR1), is a selective PAR1 agonist with an EC50 of 1.9 μM.
Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a ...
BSI-201 is a small-molecule prodrug inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase-1 (PARP-1) with potential chemosensitizing, radiosensitizing and...
AZ6102 is a moderate oral bioavailable dual inhibitor of TNKS1/2 with excellent selectivity against other PARP family enzymes including PARP-1, PARP-2 and PARP-...
Rucaparib, also known as (AG-14699 or PF-01367338, is a tricyclic indole poly(ADP-Ribose) polymerase (PARP1) inhibitor with potential chemosensitizing, radiose...
AZD2461 is a novel and potent PARP inhibitor with lower affinity to P-glycoprotein. AZD2641 is currently in Phase I clinical study. The study is being conducted...